The Impact of Oncotype DX® Recurrence Score of Paraffin-Embedded Core Biopsy Tissues in Predicting Response to Neoadjuvant Chemotherapy in Women With Breast Cancer

Breast Disease - Netherlands
doi 10.3233/bd-150199
Full Text
Abstract

Available in full text

Date
Authors
Publisher

IOS Press

Related search

Oncotype Dx Recurrence Score Among BRCA1/2 Germline Mutation Carriers With Hormone Receptors Positive Breast Cancer

International Journal of Cancer
Cancer ResearchOncology
2017English

Treatment Decisions in Estrogen Receptor-Positive Early Breast Cancer Patients With Intermediate Oncotype DX Recurrence Score Results

SpringerPlus
Multidisciplinary
2014English

Oncotype DX Breast Cancer Recurrence Score Resists Inter-Assay Reproducibility With RT2-Profiler Multiplex RT-PCR

Scientific Reports
Multidisciplinary
2019English

The ZNF217 Biomarker Predicts Low- And High-Risk Oncotype DX® Recurrence Score in ER-Positive Invasive Breast Cancers

Frontiers in Pharmacology
Pharmacology
2019English

Predictors of Recurrence in Breast Cancer Patients With a Pathologic Complete Response After Neoadjuvant Chemotherapy

British Journal of Cancer
Cancer ResearchOncology
2010English

Association Between CHEK2 H371Y Mutation and Response to Neoadjuvant Chemotherapy in Women With Breast Cancer

BMC Cancer
Cancer ResearchOncologyGenetics
2015English

Prediction of Neoadjuvant Chemotherapy Response in Breast Cancer

Journal of Medical – Clinical Research & Reviews
2019English

Value of TP53 Status for Predicting Response to Neoadjuvant Chemotherapy in Breast Cancer: A Meta-Analysis

PLoS ONE
Multidisciplinary
2012English

1830 Diagnosis of Pathological Complete Response to Neoadjuvant Chemotherapy in Breast Cancer by Minimal Invasive Biopsy Techniques

European Journal of Cancer
Cancer ResearchOncology
2015English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy